{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-424644","form_type":"8-K","ticker":"EYPT","cik":"0001314102","company_name":"EyePoint, Inc.","filed_at":"2026-10-19T11:05:19+00:00","discovered_at":"2026-10-19T11:10:02.542411+00:00","generated_at":"2026-10-19T11:10:07.730285+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.87,"calibrated_materiality_score":0.87,"confidence":"high","headline":"EyePoint's LUCIA Phase 3 DURAVYU trial misses primary BCVA non-inferiority endpoint in wet AMD","bullets":["LUCIA (475 patients) failed the primary endpoint of statistical non-inferiority in mean BCVA change vs on-label 2 mg aflibercept, despite demonstrating visual improvement.","Key secondary endpoints met: 38% reduction in treatment burden (nominal p<0.0001), 52% of eyes supplement-free and 71% receiving zero or one supplement through Week 56.","Favorable safety profile with redosing and strong anatomic control at Week 56, consistent with LUGANO (432 patients), which also missed its primary endpoint.","EyePoint will complete additional analyses of LUCIA and pooled Phase 3 datasets to assess next steps for DURAVYU in wet AMD.","DME program on track: pivotal COMO and CAPRI topline data expected Q4 2027; Phase 2 VERONA showed +7.1 letter BCVA gain and 73% supplement-free at Week 24."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-424644","json":"https://secwatch.observer/filing/0001193125-26-424644.json","markdown":"https://secwatch.observer/filing/0001193125-26-424644.md","text":"https://secwatch.observer/filing/0001193125-26-424644.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1314102/000119312526424644/0001193125-26-424644-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1314102/000119312526424644/eypt-20261019.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-19T11:10:07.730285+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}